{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T18:04:14Z","timestamp":1783101854200,"version":"3.54.6"},"reference-count":37,"publisher":"American Academy of Insurance Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Insur Med"],"published-print":{"date-parts":[[2023]]},"abstract":"<jats:p>During the past 5 decades, there have been reports of increases in the incidence and mortality rates of non-Hodgkin lymphoma (NHL) in the United States and globally. The ability to address the epidemiologic diversity, prognosis and treatment of NHL depends on the use of an accurate and consistent classification system. Historically, uniform treatment for NHL has been hampered by the lack of a systematic taxonomy of non-Hodgkin lymphoma. Before 1982, there were 6 competing classification schemes with contending terminologies for NHL: the Rappaport, Lukes-Collins, Kiel, World Health Organization, British, and Dorfman systems without consensus as to which system is most satisfactory regarding clinical relevance, scientific accuracy and reproducibility and presenting a difficult task for abstractors of incidence information. In 1982, the National Cancer Institute sponsored a workshop1 that developed a working formulation designed to: 1) provide clinicians with prognostic information for the various types of NHLs, and 2) provide a common language that might be used to compare clinical trials from various treatment centers around the world. Studies imply that prognosis is dependent on tumor stage and histology rather than the primary localization per se.2 This study utilizes the National Cancer Institute PDQ adaptation of the World Health Organization\u2019s (WHO) updated REAL (Revised European American Lymphoma) classification3 of lymphoproliferative diseases, and the SEER*Stat 8.3.6 database (released Aug 8, 2019) for diagnosis years 1975-2016. In this article, we make use of 40 years of data to examine patterns of incidence, survival and mortality, and selected cell bio-behavioral characteristics of NHL in the United States.<\/jats:p>\n        <jats:p>\n          <jats:bold>\n            <jats:italic>Objective.<\/jats:italic>\n          <\/jats:bold>\u2014To update trends in incidence and prevalence in the United States of non-Hodgkin lymphoma, examine, compare and contrast short and long-term patterns of survival and mortality, and consider the outcome impacts of anatomic location of NHL nodal and extranodal subdivisions, utilizing selected ICD-O-3 histologic oncotypes stratified by age, sex, race\/ethnicity, stage, cell behavioral morphology and histologic typology, cohort entry time-period and disease duration, employing the statistical database of the National Cancer Institute SEER*Stat 8.3.6 program for diagnosis years 1975-2016.4<\/jats:p>\n        <jats:p>\n          <jats:bold>\n            <jats:italic>Methods.\u2014<\/jats:italic>\n          <\/jats:bold>A retrospective, population-based cohort study using nationally representative data from the National Cancer Institute\u2019s (NCI) Surveillance, Epidemiology, and End Results (SEER) program to evaluate 384,651 NHL cases for diagnosis years 1975-2016 comparing multiple variables of age, sex, race, stage, cell behavioral morphology, cohort entry time-period, disease duration and histologic oncotype. Relative survival statistics were analyzed in two cohorts: 1975-1995 and 1996-2016. Survival statistics were derived from SEER*Stat Database: Incidence \u2013 SEER 9 Regs Research Data, November 2018 Submission (1975-2016) &lt;Katrina\/Rita Population Adjustment&gt; released April 2019, based on the November 2018 submission.<\/jats:p>\n        <jats:p>\n          <jats:bold>\n            <jats:italic>Results.\u2014<\/jats:italic>\n          <\/jats:bold>Incidence rates, relative frequency distributions, survival and mortality by age, sex, stage and cell behavioral morphology, of adult nodal (N) and extranodal (EN) NHL in 2 entrant time-periods as recorded in the SEER Program of the National Cancer Institute for diagnosis years 1975-2016 (SEER Stat 8.3.6) are summarized. Shifts in trends over time are identified, and the findings are correlated with prognosis, including short and long-term observed (actual), expected and relative survival, median observed and relative survival, mortality rates and excess death rates per 1000 people.<\/jats:p>\n        <jats:p>\n          <jats:bold>\n            <jats:italic>Conclusions.\u2014<\/jats:italic>\n          <\/jats:bold>Trends in SEER incidence, prevalence, survival and mortality by age, sex, race, stage, cell behavioral morphology, cohort entry time-period, relative frequency and percent distribution, were examined to provide a current epidemiologic and medical-actuarial risk assessment framework for nodal (N) and extranodal (EN) non-Hodgkin\u2019s lymphoma in the 1975-2016 timeframe.<\/jats:p>","DOI":"10.17849\/insm-50-1-1-35.1","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T16:09:55Z","timestamp":1695139795000},"page":"1-35","source":"Crossref","is-referenced-by-count":12,"title":["Non-Hodgkin Lymphoma \u2013 Nodal and Extranodal: 20-Year Comparative Mortality, Survival &amp; Biologic Behavior Analysis by Age, Sex, Race, Stage, Cell Morphology\/Histology, Cohort Entry Time-Period and Disease Duration: A Systematic Review of 384,651 Total NHL Cases Including 261,144 Nodal and 123,507 Extranodal Cases for Diagnosis Years 1975-2016: (SEER*Stat 8.3.6)"],"prefix":"10.17849","volume":"50","author":[{"given":"Anthony F.","family":"Milano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7324","reference":[{"key":"i0743-6661-50-1-1-ref1","series-title":"Cancer","first-page":"2112","article-title":"National Cancer Institute sponsored study of classifications of non-Hodgkin\u2019s lymphomas. Summary and description of a working formulation for clinical usage","volume":"49","year":"1982","unstructured":"Non-Hodgkin\u2019s Lymphoma Pathologic Classification Project.\nNational Cancer Institute sponsored study of classifications of non-Hodgkin\u2019s lymphomas. Summary and description of a working formulation for clinical usage.\nCancer.\n1982;\n49:\n2112-\n2135."},{"key":"i0743-6661-50-1-1-ref2","series-title":"Leuk Lymphoma","first-page":"131","article-title":"Primary extranodal non-Hodgkin\u2019s lymphoma in adults: clinicopathological and survival characteristics","volume":"21","author":"Economoboulos","year":"1996","unstructured":"Economoboulos\n              I,\n            \n            \n              Ashrou\n              N,\n            \n            \n              Stathakis\n              N,\n            \n          \n          et al.\n          Primary extranodal non-Hodgkin\u2019s lymphoma in adults: clinicopathological and survival characteristics.\nLeuk Lymphoma.\n1996;\n21:\n131-\n136.\n[PUBMED Abstract]"},{"key":"i0743-6661-50-1-1-ref3","series-title":"Ann Oncol","first-page":"607","article-title":"From the R.E.A.L. Classification to the upcoming WHO scheme: a step toward universal categorization of lymphoma entities?","volume":"9","author":"Pileri","year":"1998","unstructured":"Pileri\n              SA,\n            \n            \n              Milani\n              M,\n            \n            \n              Fraternali-Orcioni\n              G,\n            \n          \n          et al.\n          From the R.E.A.L. Classification to the upcoming WHO scheme: a step toward universal categorization of lymphoma entities?\n          Ann Oncol.\n1998;\n9:\n607-\n612.\n[PUBMED Abstract]"},{"key":"i0743-6661-50-1-1-ref4","series-title":"Built","article-title":"National Cancer Institute SEER*Stat software (www.seer.cancer.gov\/seerstat) version 8.3.6","year":"2019","unstructured":"Surveillance Research Program,\nNational Cancer Institute SEER*Stat software (www.seer.cancer.gov\/seerstat) version 8.3.6.,\nBuilt2019."},{"key":"i0743-6661-50-1-1-ref5","series-title":"Lancet","first-page":"848","article-title":"Non-Hodgkin lymphoma","volume":"380","author":"Shankland","year":"2012","unstructured":"Shankland\n              KR,\n            \n            \n              Armitage\n              JO,\n            \n            \n              Hancock\n              BW.\n            \n          \n          Non-Hodgkin lymphoma.\nLancet.\n2012;\n380:\n848-\n857."},{"key":"i0743-6661-50-1-1-ref6","series-title":"Blood","first-page":"2375","article-title":"THE UPDATED WHO CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES: The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","unstructured":"Swerdlow\n              SH,\n            \n            \n              Campo\n              E,\n            \n            \n              Pileri\n              SA,\n            \n          \n          et al.\n          THE UPDATED WHO CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES: The 2016 revision of the World Health Organization classification of lymphoid neoplasms.\nBlood.\n2016;\n127:\n2375-\n2390."},{"key":"i0743-6661-50-1-1-ref7","series-title":"Ann Oncol","first-page":"607","article-title":"From the R.E.A.L. Classification to the upcoming WHO scheme: a step toward universal categorization of lymphoma entities?","volume":"9","author":"Pileri","year":"1998","unstructured":"Pileri\n              SA,\n            \n            \n              Milani\n              M,\n            \n            \n              Fraternali-Orcioni\n              G,\n            \n          \n          et al.\n          From the R.E.A.L. Classification to the upcoming WHO scheme: a step toward universal categorization of lymphoma entities?\n          Ann Oncol.\n1998;\n9:\n607-\n612.\n[PUBMED Abstract]"},{"key":"i0743-6661-50-1-1-ref8","article-title":"National Cancer Institute SEER*Stat software (www.seer.cancer.gov\/seerstat): Latest Release: Version 8.3.6","year":"2019","unstructured":"Surveillance Research Program,\nNational Cancer Institute SEER*Stat software (www.seer.cancer.gov\/seerstat): Latest Release: Version 8.3.6 -\n2019."},{"key":"i0743-6661-50-1-1-ref9","series-title":"Annals of Oncology","first-page":"131","article-title":"Primary extranodal non-Hodgkin\u2019s lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry","volume":"14","author":"Krol1","year":"2003","unstructured":"Krol1\n              ADG,\n            \n            \n              le Cessie\n              S,\n            \n            \n              Snijder\n              JC,\n            \n          \n          et al.\n          Primary extranodal non-Hodgkin\u2019s lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry.\nAnnals of Oncology.\n2003;\n14:\n131-\n139."},{"key":"i0743-6661-50-1-1-ref10","series-title":"J Clin Oncol","first-page":"6415","article-title":"State-of-the-art therapeutics: marginal-zone lymphoma","volume":"23","author":"Bertoni","year":"2005","unstructured":"Bertoni\n              F,\n            \n            \n              Zucca\n              E\n            \n          :\nState-of-the-art therapeutics: marginal-zone lymphoma.\nJ Clin Oncol.\n2005;\n23:\n6415-\n6420.\n[PUBMED Abstract]"},{"key":"i0743-6661-50-1-1-ref11","series-title":"Blood","first-page":"2082","article-title":"The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance","volume":"127","author":"Zucca","year":"2016","unstructured":"Zucca\n              E,\n            \n            \n              Bertoni\n              F\n            \n          :\nThe spectrum of MALT lymphoma at different sites: biological and therapeutic relevance.\nBlood.\n2016;\n127:\n2082-\n2092.\n[PUBMED Abstract]"},{"key":"i0743-6661-50-1-1-ref12","series-title":"J Natl Cancer Inst","first-page":"1240","article-title":"Cancer surveillance series: non-Hodgkin\u2019s lymphoma incidence by histologic subtype in the United States from 1978 through 1995","volume":"92","author":"Groves","year":"2000","unstructured":"Groves\n              FD,\n            \n            \n              Linet\n              MS,\n            \n            \n              Travis\n              LB,\n            \n            \n              Devesa\n              SS.\n            \n          \n          Cancer surveillance series: non-Hodgkin\u2019s lymphoma incidence by histologic subtype in the United States from 1978 through 1995.\nJ Natl Cancer Inst.\n2000;\n92:\n1240-\n1251."},{"key":"i0743-6661-50-1-1-ref13","volume":"2019","year":"2019","unstructured":"American Cancer Society: Cancer Facts and Figures\n          2019.\nAtlanta, Ga:\nAmerican Cancer Society,\n2019."},{"key":"i0743-6661-50-1-1-ref14","series-title":"Blood","first-page":"2060","article-title":"High-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology","volume":"131","author":"Scott","year":"2018","unstructured":"Scott\n              DW,\n            \n            \n              King\n              RL,\n            \n            \n              Staiger\n              AM,\n            \n          \n          et al.\n          High-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology.\nBlood2018;\n131:\n2060-\n2064.\n[PUBMED Abstract]"},{"key":"i0743-6661-50-1-1-ref15","series-title":"N Engl J Med","first-page":"1396","article-title":"Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma","volume":"378","author":"Schmitz","year":"2018","unstructured":"Schmitz\n              R,\n            \n            \n              Wright\n              GW,\n            \n            \n              Huang\n              DW,\n            \n          \n          et al.\n          Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.\nN Engl J Med.\n2018;\n378:\n1396-\n1407.\n[PUBMED Abstract]"},{"key":"i0743-6661-50-1-1-ref16","series-title":"Int J Cancer","first-page":"645","article-title":"Non-Hodgkin\u2019s lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS\/Cancer Study Group","volume":"73","author":"Cote","year":"1997","unstructured":"Cote\n              TR,\n            \n            \n              Biggar\n              RJ,\n            \n            \n              Rosenberg\n              PS,\n            \n          \n          et al.\n          Non-Hodgkin\u2019s lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS\/Cancer Study Group.\nInt J Cancer.\n1997;\n73:\n645-\n650."},{"key":"i0743-6661-50-1-1-ref17","series-title":"J Insur Med","first-page":"116","article-title":"Comparative Mortality in HIV-Infected Patients in Denmark, 1995\u20132005","volume":"40","author":"Singer","year":"2008","unstructured":"Singer\n              RB,\n            \n            \n              Milano\n              AF.\n            \n          \n          Comparative Mortality in HIV-Infected Patients in Denmark, 1995\u20132005.\nJ Insur Med.\n2008;\n40:\n116-\n119."},{"key":"i0743-6661-50-1-1-ref18","article-title":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2018 Sub (1975-2016 varying) - Linked To County Attributes - Total U.S., 1969-2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2019, based on the November 2018 submission","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2018 Sub (1975-2016 varying) - Linked To County Attributes - Total U.S., 1969-2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2019, based on the November 2018 submission."},{"key":"i0743-6661-50-1-1-ref19","article-title":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2018 Sub (1975-2016) <Katrina\/Rita Population Adjustment>- Linked To County Attributes - Total U.S., 1969-2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2019, based on the November 2018 submission","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2018 Sub (1975-2016) <Katrina\/Rita Population Adjustment>- Linked To County Attributes - Total U.S., 1969-2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2019, based on the November 2018 submission."},{"key":"i0743-6661-50-1-1-ref20","series-title":"Medical Risks - 1991 Compend of Mortality and Morbidity","author":"Singer","year":"1994","unstructured":"Singer\n              RB,\n            \n            \n              Kita\n              MW,\n            \n            \n              Avery\n              JR\n            \n          , eds.\nMedical Risks - 1991 Compend of Mortality and Morbidity.\nWestport, Conn:\nPraeger Publishers;\n1994."},{"key":"i0743-6661-50-1-1-ref21","series-title":"Medical Selection of Life Risks","author":"Brackenridge","year":"2006","unstructured":"Brackenridge\n              RDC,\n            \n            \n              Croxson\n              RS,\n            \n            \n              Mackenzie\n              R\n            \n          , eds.\nMedical Selection of Life Risks.\n5th ed.\nNew York, NY:\nPalgrave Macmillan;\n2006:\nchaps 3-5."},{"key":"i0743-6661-50-1-1-ref22","series-title":"J Insur Med","first-page":"1","article-title":"Mortality Methodology and Analysis Seminar Text. Sponsored by the Association of Life Insurance Medical Directors of America","volume":"20","author":"Pokorski","year":"1988","unstructured":"Pokorski\n              RJ.\n            \n          \n          Mortality Methodology and Analysis Seminar Text. Sponsored by the Association of Life Insurance Medical Directors of America.\nJ Insur Med.\n1988;\n20:\n1-\n26."},{"key":"i0743-6661-50-1-1-ref23","series-title":"J Insur Med","first-page":"65","article-title":"The Cancer Mortality Risk Project \u2013 Cancer Mortality Risks by Anatomic Site: Part I \u2013 Introductory Overview; Carcinoma of the Colon: 20-Year Mortality Follow-up Derived from 1973-2013 (NCI) SEER*Stat Survival Database","volume":"47","author":"Milano","year":"2017","unstructured":"Milano\n              AF,\n            \n            \n              Singer\n              RB.\n            \n          \n          The Cancer Mortality Risk Project \u2013 Cancer Mortality Risks by Anatomic Site: Part I \u2013 Introductory Overview; Carcinoma of the Colon: 20-Year Mortality Follow-up Derived from 1973-2013 (NCI) SEER*Stat Survival Database.\nJ Insur Med.\n2017;\n47:\n65-\n94."},{"key":"i0743-6661-50-1-1-ref24","series-title":"SEER Cancer Statistics Review","author":"Howlader","year":"1975-2016","unstructured":"Howlader\n              N,\n            \n            \n              Noone\n              AM,\n            \n            \n              Krapcho\n              M,\n            \n          \n          et al (eds).\nSEER Cancer Statistics Review,\n1975-2016,\nNational Cancer Institute.\nBethesda, MD,\nhttps:\/\/seer.cancer.gov\/csr\/1975_2016\/,\nbased on November 2018 SEER data submission, posted to the SEER web site, April 2019."},{"key":"i0743-6661-50-1-1-ref25","unstructured":"Physician Data Query (PDQ).\nhttps:\/\/www.cancer.gov\/publications\/pdq"},{"key":"i0743-6661-50-1-1-ref26","series-title":"Cancer Epidemiology and Prevention","article-title":"Morphologic classification of human cancer","author":"Berg","year":"1982","unstructured":"Berg\n              JW.\n            \n          \n          Morphologic classification of human cancer. In:\nSchottenfeldD,FraumeniJF, eds.\nCancer Epidemiology and Prevention.\nPhiladelphia: Saunders;\n1982."},{"key":"i0743-6661-50-1-1-ref27","series-title":"J Clin Oncol","first-page":"5019","article-title":"Improved survival of follicular lymphoma patients in the United States","volume":"23","author":"Swenson","year":"2005","unstructured":"Swenson\n              WT,\n            \n            \n              Wooldridge\n              JE,\n            \n            \n              Lynch\n              CF,\n            \n          \n          et al.\n          Improved survival of follicular lymphoma patients in the United States.\nJ Clin Oncol.\n2005;\n23:\n5019-\n5026.\n[PUBMED Abstract]"},{"key":"i0743-6661-50-1-1-ref28","series-title":"J Clin Oncol","first-page":"1582","article-title":"Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center","volume":"24","author":"Liu","year":"2006","unstructured":"Liu\n              Q,\n            \n            \n              Fayad\n              L,\n            \n            \n              Cabanillas\n              F,\n            \n          \n          et al.\n          Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center.\nJ Clin Oncol.\n2006;\n24:\n1582-\n1589.\n[PUBMED Abstract]"},{"key":"i0743-6661-50-1-1-ref29","series-title":"AJCC Cancer Staging Manual","first-page":"937","author":"Amin","year":"2017","unstructured":"Hodgkin and non-Hodgkin lymphoma. In:\nAminMB,EdgeSB,GreeneFL,et al, eds.\nAJCC Cancer Staging Manual.\n8th ed.New York, NY:\nSpringer;\n2017:\n937-\n958."},{"key":"i0743-6661-50-1-1-ref30","series-title":"J Clin Oncol","first-page":"3059","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","unstructured":"Cheson\n              BD,\n            \n            \n              Fisher\n              RI,\n            \n            \n              Barrington\n              SF,\n            \n          \n          et al.\n          Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.\nJ Clin Oncol.\n2014;\n32:\n3059-\n3068."},{"key":"i0743-6661-50-1-1-ref31","series-title":"J Clin Oncol","first-page":"3048","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","unstructured":"Barrington\n              SF,\n            \n            \n              Mikhaeel\n              NG,\n            \n            \n              Kostakoglu\n              L,\n            \n          \n          et al.\n          Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.\nJ Clin Oncol.\n2014;\n32:\n3048-\n3058."},{"issue":"1","key":"i0743-6661-50-1-1-ref32","series-title":"Surveillance Research Program, National Cancer Institute; 2011. Technical Report","first-page":"1","article-title":"Estimating relative survival for cancer patients from the SEER Program using expected rates based on Ederer I versus Ederer II method","volume":"2011","author":"Cho","unstructured":"Cho\n              H,\n            \n            \n              Howlader\n              N,\n            \n            \n              Mariotto\n              AB,\n            \n            \n              Cronin\n              KA.\n            \n          \n          Estimating relative survival for cancer patients from the SEER Program using expected rates based on Ederer I versus Ederer II method.\nSurveillance Research Program, National Cancer Institute; 2011. Technical Report.\n2011;\n1:\n1-\n17.\nAvailable from:\nhttps:\/\/surveillance.cancer.gov\/reports\/."},{"key":"i0743-6661-50-1-1-ref33","series-title":"N Engl J Med","first-page":"1378","article-title":"Epidemiologic Signatures in Cancer","volume":"381","author":"Welch","year":"2019","unstructured":"Welch\n              HG,\n            \n            \n              Kramer\n              BS,\n            \n            \n              Black\n              WC.\n            \n          \n          Epidemiologic Signatures in Cancer.\nN Engl J Med.\n2019;\n381:\n1378-\n1386."},{"key":"i0743-6661-50-1-1-ref34","series-title":"Ann Oncol","first-page":"3","article-title":"Lymphoma classification\u2014from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms [review]","volume":"11","author":"Harris","year":"2000","unstructured":"Harris\n              NL,\n            \n            \n              Jaffe\n              ES,\n            \n            \n              Diebold\n              J,\n            \n          \n          et al.\n          Lymphoma classification\u2014from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms [review].\nAnn Oncol.\n2000;\n11(Suppl 1):\n3-\n10."},{"key":"i0743-6661-50-1-1-ref35","series-title":"N Engl J Med","first-page":"1507","article-title":"Chimeric Antigen Receptor T Cells for Sustained Remission in Leukemia","volume":"371","author":"Maud","year":"2014","unstructured":"Maud\n              SL,\n            \n            \n              Frey\n              N,\n            \n            \n              Shaw\n              PA,\n            \n          \n          et al.\n          Chimeric Antigen Receptor T Cells for Sustained Remission in Leukemia.\nN Engl J Med.\n2014;\n371:\n1507-\n1517."},{"key":"i0743-6661-50-1-1-ref36","series-title":"J Clin Oncol","first-page":"540","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","unstructured":"Kochenderfer\n              JN,\n            \n            \n              Dudley\n              ME,\n            \n            \n              Kassim\n              SH,\n            \n          \n          et al.\n          Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.\nJ Clin Oncol.\n2015;\n33:\n540-\n549."},{"key":"i0743-6661-50-1-1-ref37","series-title":"Cancer","first-page":"2154","article-title":"Adoptive T-Cell Therapy: An Overview of Obstacles and Opportunities","volume":"123","author":"Baruch","year":"2017","unstructured":"Baruch\n              EN,\n            \n            \n              Berg\n              AL,\n            \n            \n              Besser\n              MJ,\n            \n          \n          et al.\n          Adoptive T-Cell Therapy: An Overview of Obstacles and Opportunities.\nCancer.\n2017;\n123:\n2154-\n2162.\n(2017 American Cancer Society)"}],"container-title":["Journal of Insurance Medicine"],"original-title":[],"link":[{"URL":"https:\/\/jim.kglmeridian.com\/view\/journals\/insm\/50\/1\/article-p1.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/jim\/article-pdf\/50\/1\/1\/3263290\/i0743-6661-50-1-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jim.kglmeridian.com\/downloadpdf\/journals\/insm\/50\/1\/article-p1.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jim.kglmeridian.com\/downloadpdf\/journals\/insm\/50\/1\/article-p1.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:39:14Z","timestamp":1747355954000},"score":1,"resource":{"primary":{"URL":"https:\/\/jim.kglmeridian.com\/view\/journals\/insm\/50\/1\/article-p1.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":37,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.17849\/insm-50-1-1-35.1","relation":{},"ISSN":["0743-6661"],"issn-type":[{"value":"0743-6661","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}